HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.
The only producer of quality-controlled redox variants of HMGB1
Featured news
Targeting HMGB1 could represent a novel therapeutic approach for mental health disorders related to stroke and sepsis.
World Mental Health Day, occurring on the 10th of October, recalls to us the importance of researches linking inflammation and mental health disorders, in particular major depressive disorder (MDD).
HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.
Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…
Disulfide HMGB1
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…
Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…
From our LinkedIn profile
Featured Products
About us
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…
